MVP Act
Official title: A bill to amend title XIX of the Social Security Act to codify value-based purchasing arrangements under the Medicaid program and reforms related to price repo… Show full official titleShow less
Official title: A bill to amend title XIX of the Social Security Act to codify value-based purchasing arrangements under the Medicaid program and reforms related to price reporting under such arrangements, and for other purposes.
| Date | Chamber | What was voted on | Result | Yes–No | |
|---|---|---|---|---|---|
| May 11, 2004 | Senate · vote #91 | On Passage of the Bill S. 1637 | Passed | 92–5 | See who voted → |
| May 11, 2004 | Senate · vote #87 | On the Cloture Motion S. 1637 | Agreed To | 90–8 | See who voted → |
| Apr 7, 2004 | Senate · vote #67 | On the Cloture Motion S. 1637 | Rejected | 50–47 | See who voted → |
| Mar 24, 2004 | Senate · vote #60 | On the Cloture Motion S. 1637 | Rejected | 51–47 | See who voted → |
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Read twice and referred to the Committee on Finance.
Medicaid VBPs for Patients Act or the MVP Act
This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. (Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.)
The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.
Additionally, the bill (1) exempts sales of drugs that are made under value-based purchasing arrangements from calculations of the manufacturer average sales price for purposes of payments under Medicare medical services, if the manufacturer reports multiple best prices under Medicaid in accordance with the bill's changes; and (2) requires the Centers for Medicare & Medicaid Services to issue guidance on how state Medicaid programs may cover drugs in inpatient settings via value-based purchasing arrangements.
- Introduced in Senate Formatted Text PDF Formatted XML
- BIOTECHNOLOGY INNOVATION ORGANIZATION
- AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
- PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
- ORCHARD THERAPEUTICS NORTH AMERICA
- TIBER CREEK GROUP
- AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
Bodies those filers lobbied
- HOUSE OF REPRESENTATIVES
- SENATE
- Centers For Medicare and Medicaid Services (CMS)
- Health & Human Services, Dept of (HHS)
- Labor, Dept of (DOL)
- Executive Office of the President (EOP)
- Food & Drug Administration (FDA)
- Patent & Trademark Office (PTO)
Cite this page
U.S. Congress. (2026). S. 1637: MVP Act. 119th Congress. Open America. https://openamerica.io/bill/119-S-1637/
"S. 1637: MVP Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-1637/.
S. 1637, 119th Cong. (2026), https://openamerica.io/bill/119-S-1637/.
[S. 1637: MVP Act](https://openamerica.io/bill/119-S-1637/)